Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism

Journal of Clinical Microbiology

Volumn 50, Issue 8, 2012, Pages 2674-2680

  Camps, Simone M T ^a   Rijs, Antonius J M M ^a   Klaassen, Corné H W ^b   Meis, Jacques F ^a,b   O'Gorman, Céline M ^c   Dyer, Paul S ^c   Melchers, Willem J G ^a   Verweij, Paul E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; FUNGAL DNA; ITRACONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; EUROPE; FUNGAL REPRODUCTION; FUNGUS ISOLATION; FUNGUS TRANSMISSION; GENE MUTATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; IN VITRO STUDY; MICROSATELLITE MARKER; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; MOLECULAR PHYLOGENY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; AZOLES; CROSSES, GENETIC; CYTOCHROME P-450 ENZYME SYSTEM; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; EUROPE; FUNGAL PROTEINS; GENETIC VARIATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; MUTATION; RECOMBINATION, GENETIC; SEQUENCE ANALYSIS, DNA;

ASPERGILLUS FUMIGATUS;

EID: 84864401552     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00335-12     Document Type: Article

References (41)

1. Araujo R, Amorim A, Gusmao L. 2010. Genetic diversity of Aspergillus fumigatus in indoor hospital environments. Med. Mycol. 48:832-838.
2. Balajee SA, de Valk HA, Lasker BA, Meis JF, Klaassen CH. 2008. Utility of a microsatellite assay for identifying clonally related outbreak isolates of Aspergillus fumigatus. J. Microbiol. Methods 73:252-256.
3. Brunner PC, Stefanato FL, McDonald BA. 2008. Evolution of the CYP51 gene in Mycosphaerella graminicola: evidence for intragenic recombination and selective replacement. Mol. Plant Pathol. 9:305-316. (Pubitemid 351550682)
4. Burgel PR, et al. 2012. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob. Agents Chemother. 56:869-874.
5. Camps SM, et al. 2012. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob. Agents Chemother. 56:10-16.
6. Chen J, Li H, Li R, Bu D, Wan Z. 2005. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J. Antimicrob. Chemother. 55:31-37. (Pubitemid 40192611)
7. Chowdhary AS, et al. 2012. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J. Antimicrob. Chemother. 67:362-366.
8. de Valk HA, et al. 2005. Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates. J. Clin. Microbiol. 43:4112-4120.
9. Garcia-Effron G, et al. 2005. Differences in interactions between azole drugs related to modifications in the 14-α sterol demethylase gene (cyp51A) of Aspergillus fumigatus. Antimicrob. Agents Chemother. 49: 2119-2121. (Pubitemid 40631636)
10. Hodiamont CJ, et al. 2009. Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med. Mycol. 47: 217-220.
11. Howard SJ, et al. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
12. Howard SJ, Pasqualotto AC, Denning DW. 2010. Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin. Microbiol. Infect. 16:683-688.
13. Hurst SF, et al. 2009. Interlaboratory reproducibility of a single-locus sequence-based method for strain typing of Aspergillus fumigatus. J. Clin. Microbiol. 47:1562-1564.
14. Kidd SE, Zulkepeli NA, Slavin MA, Morrissey CO. 2009. Utility of a proposed CSP typing nomenclature for Australian Aspergillus fumigatus isolates: identification of additional CSP types and suggested modifications. J. Microbiol. Methods 78:223-226.
15. Klaassen CH, de Valk HA, Balajee SA, Meis JF. 2009. Utility of CSP typing to sub-type clinical Aspergillus fumigatus isolates and proposal for a new CSP type nomenclature. J. Microbiol. Methods 77:292-296.
16. Klaassen CH, Gibbons JG, Fedorova ND, Meis JF, Rokas A. 2012. Evidence for genetic differentiation and variable recombination rates among Dutch populations of the opportunistic human pathogen Aspergillus fumigatus. Mol. Ecol. 21:57-70.
17. Kretschmer M, et al. 2009. Fungicide-driven evolution and molecular basis of multidrug resistance in field populations of the grey mould fungus Botrytis cinerea. PLoS Pathog. 5:e1000696. doi:10.1371/journal. ppat.1000696.
18. Lockhart SR, et al. 2011. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob. Agents Chemother. 55:4465-4468.
19. Mavridou E, Bruggemann RJ, Melchers WJ, Mouton JW, Verweij PE. 2010. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob. Agents Chemother. 54:860-865.
20. Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW. 2010. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob. Agents Chemother. 54:4758-4764.
21. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez- Tudela JL. 2004. Substitutions at methionine 220 in the 14α- sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob. Agents Chemother. 48:2747-2750. (Pubitemid 38823458)
22. Mellado E, et al. 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51:1897-1904. (Pubitemid 46903071)
23. Mortensen KL, et al. 2011. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J. Clin. Microbiol. 49:2243-2251.
24. Mortensen KL, et al. 2010. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob. Agents Chemother. 54:4545-4549.
25. O'Gorman CM, Fuller HT, Dyer PS. 2009. Discovery of a sexual cycle in the opportunistic fungal pathogen Aspergillus fumigatus. Nature 457:471-474.
26. Paoletti MC, et al. 2005. Evidence for sexuality in the opportunistic fungal pathogen Aspergillus fumigatus. Curr. Biol. 15:1242-1248.
27. Snelders E, et al. 2012. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One 7:e31801. doi: 10.1371/journal.pone.0031801.
28. Snelders E, et al. 2009. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl. Environ. Microbiol. 75: 4053-4057.
29. Snelders E, Melchers WJ, Verweij PE. 2011. Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis? Future Microbiol. 6:335-347.
30. Snelders E, et al. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5:e219. doi:10.1371/journal.pmed.0050219.
31. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). 2008. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of anti-fungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14: 982-984.
32. Sugui JA, et al. 2011. Identification and characterization of an Aspergillus fumigatus "supermater" pair. mBio. 2(6):e00234-11. doi:10.1128/ mBio.00234-11.
33. Torriani SF, Brunner PC, McDonald BA, Sierotzki H. 2009. QoI resistance emerged independently at least 4 times in European populations of Mycosphaerella graminicola. Pest Manag. Sci. 65:155-162.
34. van der Linden JW, Arendrup MC, Verweij PE, SCARE-Network. 2011. Prospective international surveillance of azole resistance in Aspergillus fumigatus (SCARE Network), abstr M-490. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Chicago, IL.
35. van der Linden JW, et al. 2009. Azole-resistant central nervous system aspergillosis. Clin. Infect. Dis. 48:1111-1113.
36. van der Linden JW, et al. 2011. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg. Infect. Dis. 17:1846-1854.
37. van Leer-Buter C, Takes RP, Hebeda KM, Melchers WJ, Verweij PE. 2007. Aspergillosis - and a misleading sensitivity result. Lancet 370:102.
38. Verweij PE, Howard SJ, Melchers WJ, Denning DW. 2009. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updat. 12:141-147.
39. Verweij PE, Mellado E, Melchers WJ. 2007. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356:1481-1483.
40. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. 2009. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect. Dis. 9:789-795.
41. Warris A, Weemaes CM, Verweij PE. 2002. Multidrug resistance in Aspergillus fumigatus. N. Engl. J. Med. 347:2173-2174.